• The company is increasingly concentrating on its core business
• Christiane Bardroff takes over the global management clinical and commercial manufacturing, engineering and technology operations, and production automation

LAUPHEIM, Germany, Nov. 16, 2022 (GLOBE NEWSWIRE) — Rentschler Biopharma SE, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), today announced the appointment of Christiane Bardroff as Chief Operating Officer (COO), effective December announced January 2022. With this addition to the Management Board, Rentschler Biopharma strengthens its focus on its core business to ensure it delivers the highest quality products and services to its customers and partners. Ms. Bardroff will lead clinical and commercial manufacturing, engineering and technology operations, and production automation, leading a highly skilled, dedicated and agile team.

With more than 15 years of experience in the biopharmaceutical industry, mainly in large corporations, with a focus on operations and automation, including overall responsibility for the construction of new biotechnological plants, Christiane Bardroff brings extensive knowledge to her position. She has applied her experience as part of global leadership teams and has always been committed to promoting and developing people. Over the past few months, the Board has been impressed by the success of Ms. Bardroff’s contribution to Rentschler Biopharma as Senior Vice President (SVP) Client Program Management and SVP Clinical and Commercial Manufacturing.

Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma SE, said: “I am very pleased that Christiane Bardroff will take on the important role of Chief Operating Officer. Our goal at Rentschler is to create value in the long term and to reliably provide our customers with first-class services.Christiane Bardroff has impressively demonstrated in the past few months that she fully shares our values ​​and…